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Introduction {#ehf212406-sec-0006}
============

Heart failure (HF) is recognized as the true epidemic of the 21st century, affecting 1--2% of the adult population in developed countries, with a prevalence of ≥10% among those aged 70 years and older.[1](#ehf212406-bib-0001){ref-type="ref"} Despite effective medication, left ventricular assist devices, and surgeries that have improved patient survival and comorbidities, replacement of the irreparably injured heart by a donor organ is the only option in some cases. However, this is often impaired by limited donors, organ rejection, and receptors that need chronic immunosuppression, which greatly reduces the patient\'s quality of life.[2](#ehf212406-bib-0002){ref-type="ref"} In this context, cell‐based therapy constitutes a promising option to restore damaged heart tissue.[3](#ehf212406-bib-0003){ref-type="ref"}, [4](#ehf212406-bib-0004){ref-type="ref"} Autologous cell transplantation is preferred for regenerative purposes because there is no risk of immune rejection. However, the use of autologous cells has some potential limitations. In general, high cell numbers are not immediately available from the same recipient. Moreover, cells isolated from elderly donors show decreased differentiation and regenerative capabilities, resulting in disappointing treatment outcomes. To overcome these limitations, therapeutic strategies are using allogeneic cells despite the need for human leukocyte antigen (HLA) matching between the donor and recipient.

Histocompatibility is mainly determined by the major histocompatibility complex genes (termed HLA in humans), the most polymorphic genes in the human genome, which are located on a 3.6 Mb region on chromosome 6p21. The HLA genes have important roles in immune system regulation.[5](#ehf212406-bib-0005){ref-type="ref"}, [6](#ehf212406-bib-0006){ref-type="ref"}, [7](#ehf212406-bib-0007){ref-type="ref"} Mainly, the HLA molecules present antigens to T lymphocytes that direct the immune response and prevent autoreactivity. It is important to note that the immune response against HLA antigens is a major obstacle in organ and haematopoietic stem cell transplantation. Currently, HLA typing is used to search for an adult HLA match or cord blood donors to prevent graft‐versus‐host disease and graft rejection during transplantation.[8](#ehf212406-bib-0008){ref-type="ref"}, [9](#ehf212406-bib-0009){ref-type="ref"}, [10](#ehf212406-bib-0010){ref-type="ref"}, [11](#ehf212406-bib-0011){ref-type="ref"}, [12](#ehf212406-bib-0012){ref-type="ref"} Thus, to increase the success of the functional engraftment of a variety of cell suspensions or cell‐embedded implants, there is a need for ready‐to‐use banks of HLA homozygous stem cells covering the largest number of HLA combinations.

In this field of study, next‐generation sequencing (NGS) approaches are based on amplification of the selected regions by PCR followed by massively parallel sequencing of the amplicons. In recent years, different HLA typing strategies by NGS have been developed that provide high throughput sequencing, unambiguous high‐resolution results, and reduced costs per sample.[13](#ehf212406-bib-0013){ref-type="ref"}, [14](#ehf212406-bib-0014){ref-type="ref"}, [15](#ehf212406-bib-0015){ref-type="ref"}, [16](#ehf212406-bib-0016){ref-type="ref"}

Thus, the aim of this study was to perform a high‐resolution exploratory HLA analysis in a cohort of patients with HF to determine the HLA‐A, ‐B, ‐C, ‐DRB1, and ‐DQB1 allele and haplotype frequencies by NGS and develop conveniently designed donor panels. These data should maximize the match probabilities for this patient population and improve potential allogeneic cell therapy outcomes.

Methods {#ehf212406-sec-0007}
=======

Study population {#ehf212406-sec-0008}
----------------

Our study cohort included 247 ambulatory patients who attended a multidisciplinary HF unit (*Table* [1](#ehf212406-tbl-0001){ref-type="table"}). The referral inclusion criteria are described elsewhere.[17](#ehf212406-bib-0017){ref-type="ref"}, [18](#ehf212406-bib-0018){ref-type="ref"} All patients attended follow‐up visits at regular predefined intervals and additional visits when required in cases of decompensation. Each subject provided their written informed consent prior to participation. The study protocol was approved by the Clinical Research Ethics Committee of our institution (reference number PI‐17‐044) and was designed in accordance with the principles outlined in the 2013 revision of the Declaration of Helsinki of 1975.[19](#ehf212406-bib-0019){ref-type="ref"} Patients provide specific ancestry data.

###### 

Baseline demographic, clinical, and biochemical data of the study participants

                                                          *n* = 247
  ------------------------------------------------------- ------------------
  Age (years)                                             68.7 ± 12.2
  Male sex                                                209 (84.6%)
  Aetiology                                               
  Ischaemic heart disease                                 152 (61.5%)
  Dilated CM                                              42 (17%)
  Hypertensive CM                                         9 (3.6%)
  Alcoholic CM                                            12 (4.9%)
  Drug‐induced CM                                         4 (1.6%)
  Valvular disease                                        13 (5.3)
  Hypertrophic CM                                         5 (2.0%)
  Other                                                   10 (4%)
  HF duration (months)                                    60 (14--119)
  LVEF                                                    29.5% ± 6.5
  NYHA functional class                                   
  I                                                       8 (3.2%)
  II                                                      156 (63.2%)
  III                                                     81 (32.8%)
  IV                                                      2 (0.8%)
  Co‐morbidities                                          
  Hypertension                                            182 (73.7%)
  Diabetes mellitus                                       112 (45.3%)
  COPD                                                    71 (28.7%)
  Renal failure[a](#ehf212406-note-0004){ref-type="fn"}   146 (59.1%)
  Anaemia[b](#ehf212406-note-0005){ref-type="fn"}         116 (47%)
  Atrial fibrillation/flutter                             100 (40.5%)
  Biochemical                                             
  Na                                                      139 ± 3.9
  Haemoglobin                                             12.9 ± 1.6
  eGFR                                                    55.5 ± 25.2
  NTproBNP                                                1673 (702--4115)
  Treatments                                              
  ACEI/ARB                                                207 (83.8%)
  Beta‐blockers                                           234 (94.7%)
  MRA                                                     171 (69.2%)
  Loop diuretics                                          214 (86.6%)
  Digoxin                                                 70 (28.3%)
  Ivabradine                                              38 (15.4%)
  Statins                                                 199 (80.6%)
  ICD                                                     83 (33.6%)
  CRT                                                     51 (20.6%)

ACEI, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; CM, cardiomyopathy; CRT, cardiac resynchronization therapy; ICD, implantable cardioverter device; LVEF, left ventricular ejection fraction; MRA: mineral corticoid receptor antagonist; NYHA, New York Heart Association.

Data expressed as mean ± standard deviation, median (25th--75th percentiles), or absolute number (percentage).

eGFR (CKD‐EPI) \<60 mL/min/1.73 m^2^.

Hb \< 12 g/dL in women and \<13 g/dL in men.

Blood extraction and processing {#ehf212406-sec-0009}
-------------------------------

Blood samples (\~3 mL) were collected into EDTA tubes via standard forearm venipuncture performed between 9:00 a.m. and 11:00 a.m. and were processed within 4 h after collection. Samples and data from patients included in this study were processed and collected by the IGTP‐HUGTP Biobank from the Spanish National Biobanks Network of Instituto de Salud Carlos III (PT13/0010/0009) and Tumour Bank Network of Catalonia. All laboratory measurements were performed by staff blinded to the patients\' clinical characteristics. DNA was extracted from peripheral blood using the QIAsymphony DNA purification system (Qiagen, Toronto, Canada) according to the manufacturer\'s protocol.

Human leukocyte antigen typing {#ehf212406-sec-0010}
------------------------------

HLA‐A, ‐B, ‐C, ‐DRB1, and ‐DQB1 were analysed by NGS using the Illumina MiSeq instrument. Focusing on key exons, the analysis characterized HLA exons 2 to 4 for class I alleles and exons 2 and 3 for class II alleles using the NGSengine software (version 2.8.0, GenDX, Netherlands) and the November 2017 IPD‐IMGT/HLA database 3.30.0, as the allele reference library. The HLA allele frequencies were estimated using PyPop software (version <http://www.pypop.org>).

Human leukocyte antigen haplotype determination {#ehf212406-sec-0011}
-----------------------------------------------

We determined the HLA haplotype by complete typing of HLA‐A, ‐B, ‐C, ‐DRB1, and ‐DQB1. The haplotypes were not determined by segregation because no parents\' samples were available. The HLA haplotype estimation was performed using HaploStats (<http://www.haplostats.org>) software based on haplotype frequencies. The haplotypes were counted using Microsoft Excel. The exact test for deviation from Hardy--Weinberg Equilibrium was evaluated by PyPop software, which uses an algorithm to estimate the *P*‐value. Also, PyPop analyses were performed to estimate the haplotype, linkage disequilibrium (D), and relative linkage disequilibrium (D\').

Results {#ehf212406-sec-0012}
=======

*Table* [1](#ehf212406-tbl-0001){ref-type="table"} shows the clinical characteristics of the studied population. In general, patients were middle‐aged and predominantly male, frequently had an ischaemic aetiology, were in NYHA functional class II or III, and were treated following contemporary guidelines. Within the cohort of HF patients, we measured the HLA‐A, ‐B, ‐C, ‐DRB1, and ‐DQB1 allele and haplotype frequencies using whole genomic DNA extracted from peripheral blood samples and high‐resolution NGS technology. While HLA class I alleles were defined based on the sequences of exons 2, 3, and 4, HLA class II alleles were designated based on the sequences of exons 2 and 3. Once HLA typing was performed, we noticed that all patients were heterozygous at the five HLA loci. Furthermore, the genotype frequencies of all five HLA loci were in Hardy--Weinberg equilibrium proportions.

In this patient cohort, the number of distinct HLA alleles were 30 for HLA‐A, 56 for HLA‐B, 23 for HLA‐C, 36 for HLA‐DRB1, and 15 for HLA‐DQB1. Three HLA‐A alleles, A\*02:01 (24.09%), A\*01:01 (13.36%), and A\*24:02 (10.12%), were the most frequent HLA‐A alleles. Eleven of the HLA‐A alleles identified (36.66%) appeared less than 1%. With regard to HLA‐B, B\*44:03 (9.31%), B\*18:01 (7.49%), B\*44:02 (7.29%), B\*08:01 (6.28%), B\*51:01 (6.28%), and B\*07:02 (5.47%) exhibited the highest frequencies. Twenty‐nine of the HLA‐B alleles (32%) appeared less than 1%. As for HLA‐C, three alleles, C\*07:01 (13.36%), C\*04:01 (12.96%), and C\*05:01 (11.74%), exhibited the most frequencies. Almost one‐quarter of the HLA‐C alleles appeared with a frequency less than 1% (*Table* [2](#ehf212406-tbl-0002){ref-type="table"}).

###### 

Class I allele frequencies in heart failure patients

  HLA‐A        *N*   AF       HLA‐B         *N*   AF       HLA‐C        *N*   AF
  ------------ ----- -------- ------------- ----- -------- ------------ ----- --------
  *A\*02:01*   119   24.09    *B\*44:03*    46    9.31     *C\*07:01*   66    13.36
  *A\*01:01*   66    13.36    *B\*18:01*    37    7.49     *C\*04:01*   64    12.96
  *A\*24:02*   50    10.12    *B\*44:02*    36    7.29     *C\*05:01*   58    11.74
  *A\*03:01*   46    9.31     *B\*08:01*    31    6.28     *C\*06:02*   47    9.51
  *A\*29:02*   35    7.09     *B\*51:01*    31    6.28     *C\*16:01*   38    7.69
  *A\*11:01*   31    6.28     *B\*07:02*    27    5.47     *C\*07:02*   33    6.68
  *A\*26:01*   19    3.85     *B\*14:02*    21    4.25     *C\*12:03*   32    6.48
  *A\*30:02*   15    3.04     *B\*38:01*    18    3.64     *C\*08:02*   24    4.86
  *A\*32:01*   14    2.83     *B\*35:01*    18    3.64     *C\*01:02*   22    4.45
  *A\*31:01*   12    2.43     *B\*50:01*    17    3.44     *C\*02:02*   21    4.25
  *A\*23:01*   10    2.02     *B\*15:01*    16    3.24     *C\*03:03*   17    3.44
  *A\*68:01*   9     1.82     *B\*57:01*    14    2.83     *C\*15:02*   14    2.83
  *A\*33:01*   8     1.62     *B\*49:01*    14    2.83     *C\*03:04*   14    2.83
  *A\*68:02*   8     1.62     *B\*45:01*    13    2.63     *C\*12:02*   9     1.82
  *A\*25:01*   8     1.62     *B\*27:05*    12    2.43     *C\*14:02*   7     1.42
  *A\*30:01*   8     1.62     *B\*40:01*    11    2.23     *C\*17:01*   7     1.42
  *A\*02:05*   7     1.42     *B\*52:01*    10    2.02     *C\*15:05*   6     1.21
  *A\*33:03*   5     1.01     *B\*35:03*    10    2.02     *C\*03:02*   3     0.61
  *A\*66:01*   5     1.01     *B\*53:01*    9     1.82     *C\*05:09*   3     0.61
  *A\*03:02*   4     0.81     *B\*40:02*    7     1.42     *C\*02:10*   3     0.61
  *A\*02:02*   3     0.61     *B\*37:01*    7     1.42     *C\*07:04*   3     0.61
  *A\*69:01*   3     0.61     *B\*39:01*    7     1.42     *C\*16:02*   2     0.40
  *A\*24:03*   2     0.40     *B\*07:05*    6     1.21     *C\*15:06*   1     0.20
  *A\*74:03*   1     0.20     *B\*35:02*    6     1.21                        
  *A\*02:03*   1     0.20     *B\*58:01*    6     1.21                        
  *A\*26:08*   1     0.20     *B\*13:02*    6     1.21                        
  *A\*30:04*   1     0.20     *B\*56:01*    5     1.01                        
  *A\*01:02*   1     0.20     *B\*41:01*    4     0.81                        
  *A\*29:01*   1     0.20     *B\*35:08*    4     0.81                        
  *A\*24:10*   1     0.20     *B\*39:06*    4     0.81                        
                              *B\*41:02*    4     0.81                        
                              *B\*15:03*    3     0.61                        
                              *B\*15:17*    3     0.61                        
                              *B\*14:01*    3     0.61                        
                              *B\*55:01*    3     0.61                        
                              *B\*44:05*    3     0.61                        
                              *B\*40:06*    2     0.40                        
                              *B\*50:02*    2     0.40                        
               494   100.00                                             494   100.00
                              *B\*51:08*    1     0.20                        
                              *B\*39:24*    1     0.20                        
                              *B\*15:09*    1     0.20                        
                              *B\*27:03*    1     0.20                        
                              *B\*18:03*    1     0.20                        
                              *B\*57:03*    1     0.20                        
                              *B\*51:02*    1     0.20                        
                              *B\*78:01*    1     0.20                        
                              *B\*35:30*    1     0.20                        
                              *B\*47:01*    1     0.20                        
                              *B\*27:12*    1     0.20                        
                              *B\*15:24*    1     0.20                        
                              *B\*27:02*    1     0.20                        
                              *B\*44:130*   1     0.20                        
                              *B\*15:16*    1     0.20                        
                              *B\*15:18*    1     0.20                        
                              *B\*46:01*    1     0.20                        
                              *B\*39:02*    1     0.20                        
                                            494   100.00                      

AF, allelic frequency; *N*, number of observed alleles.

The most likely HLA‐DRB1 alleles were DRB1\*07:01 (14.78%) and DRB1\*03:01 (13.16%). Eleven HLA‐DRB1 alleles (22.22%) were observed less than 1%. The most frequent alleles were DQB1\*03:01 (15.38%), DQB1\*05:01 (14.57%), DQB1\*02:01 (13.36%), and DQB1\*02:02 (13.36%). All HLA‐DQB1 alleles appeared six or more times (*Table* [3](#ehf212406-tbl-0003){ref-type="table"}).

###### 

Class II allele frequencies in heart failure patients

  HLA‐DRB1        *N*   AF       HLA‐DQB1        *N*   AF
  --------------- ----- -------- --------------- ----- --------
  *DRB1\*07:01*   73    14.78    *DQB1\*03:01*   76    15.38
  *DRB1\*03:01*   65    13.16    *DQB1\*05:01*   72    14.57
  *DRB1\*15:01*   40    8.10     *DQB1\*02:01*   66    13.36
  *DRB1\*13:01*   36    7.29     *DQB1\*02:02*   66    13.36
  *DRB1\*01:01*   35    7.09     *DQB1\*03:02*   48    9.72
  *DRB1\*11:01*   27    5.47     *DQB1\*06:02*   38    7.69
  *DRB1\*11:04*   23    4.66     *DQB1\*06:03*   36    7.29
  *DRB1\*01:02*   21    4.25     *DQB1\*03:03*   22    4.45
  *DRB1\*04:04*   17    3.44     *DQB1\*04:02*   15    3.04
  *DRB1\*13:02*   17    3.44     *DQB1\*05:03*   13    2.63
  *DRB1\*04:05*   13    2.63     *DQB1\*05:02*   12    2.43
  *DRB1\*09:01*   11    2.23     *DQB1\*06:04*   9     1.82
  *DRB1\*11:02*   10    2.02     *DQB1\*06:09*   8     1.62
  *DRB1\*04:02*   10    2.02     *DQB1\*06:01*   7     1.42
  *DRB1\*16:01*   10    2.02     *DQB1\*03:19*   6     1.21
  *DRB1\*08:01*   10    2.02                           
  *DRB1\*04:03*   9     1.82                           
  *DRB1\*10:01*   9     1.82                           
  *DRB1\*15:02*   8     1.62                           
  *DRB1\*14:54*   7     1.42                           
  *DRB1\*04:01*   6     1.21                           
  *DRB1\*13:03*   6     1.21                           
  *DRB1\*04:07*   5     1.01                           
  *DRB1\*01:03*   5     1.01                           
  *DRB1\*12:01*   5     1.01                           
  *DRB1\*14:04*   4     0.81                           
  *DRB1\*04:06*   2     0.40                           
  *DRB1\*13:05*   2     0.40                           
  *DRB1\*16:02*   1     0.20                           
  *DRB1\*15:03*   1     0.20                           
  *DRB1\*04:11*   1     0.20                           
  *DRB1\*14:05*   1     0.20                           
  *DRB1\*13:11*   1     0.20                           
  *DRB1\*08:04*   1     0.20                           
  *DRB1\*04:37*   1     0.20                           
  *DRB1\*12:02*   1     0.20                           
                  494   100.00                   494   100.00

AF, allele frequency; *N*, number of observed alleles.

Importantly, the most frequent HLA alleles in this HF population are in line with the most frequent HLA alleles presented in our reference population. In particular, we used as reference database all NGS‐typed samples collected in the bank of samples of Blood and Tissue Bank (Barcelona, Spain). Because Blood and Tissue Bank implemented NGS for typing their samples in 2015, they have assessed more than 15 000 samples from our area (data not shown). Also, we used the Allele Frequency Net Database as a reference (<http://allelefrequencies.net>).

We likewise studied the HLA allele, taking into account the two main etiological causes of HF in our cohort of patients. Of note, the cohorts of patients with dilated cardiomyopathy (DCM) and ischaemic HF (IHF) showed some differences on HLA allele frequencies. Regarding DCM patients, HLA‐A\*03:01 (5.95%), HLA‐B\*08:01 (1.19%), and HLA‐DRB1\*03:01 (8.33%) were less represented as compared with the IHF group and reference database. On the contrary, HLA‐C\*04:01 (20.24%), HLA‐DRB1\*04:03 (3.57%), HLA‐DRB1\*04:04 (4.76%), and HLA‐DRB1\*04:05 (3.57%) were more common on patients with DCM. On the other hand, the IHF patients had over represented HLA‐DQB1\*05:01 (16.45%) and HLA‐C\*05:01 (12.50%). HLA‐DQB1\*03:01 (12.50%) was also less expressed in this cohort of patients.

When ethnicity of our cohort of HF patients was considered, we identified 383 unique haplotypes from the 494 five‐loci haplotypes analysed, five of which were present six or more times (*Table* [*S1*](#ehf212406-supitem-0001){ref-type="supplementary-material"}). The most common five‐loci haplotype detected was A\*01:01‐B\*08:01‐C\*07:01‐DRB1\*03:01‐DQB1\*02:01 (3.04%), which had a haplotype frequency of 6.07% per patient (*Table* [4](#ehf212406-tbl-0004){ref-type="table"}). Remarkably, 31.17% of patients would be covered by the 11 most frequent HLA haplotypes (*Figure* [*1*](#ehf212406-fig-0001){ref-type="fig"}).

###### 

The most frequent haplotypes in heart failure patients

  ID   Haplotypes                                                         *N*   HF     PHF
  ---- ------------------------------------------------------------------ ----- ------ -------
  1    *A\*01:01*, *B\*08:01*, *C\*07:01*, *DRB1\*03:01*, *DQB1\*02:01*   15    3.04   6.07
  2    *A\*29:02*, *B\*44:03*, *C\*16:01*, *DRB1\*07:01*, *DQB1\*02:02*   11    2.23   4.45
  3    *A\*30:02*, *B\*18:01*, *C\*05:01*, *DRB1\*03:01*, *DQB1\*02:01*   10    2.02   4.05
  4    *A\*23:01*, *B\*44:03*, *C\*04:01*, *DRB1\*07:01*, *DQB1\*02:02*   7     1.42   2.83
  5    *A\*02:01*, *B\*08:01*, *C\*07:01*, *DRB1\*03:01*, *DQB1\*02:01*   6     1.21   2.43
  6    *A\*33:01*, *B\*14:02*, *C\*08:02*, *DRB1\*01:02*, *DQB1\*05:01*   6     1.21   2.43
  7    *A\*02:01*, *B\*18:01*, *C\*05:01*, *DRB1\*03:01*, *DQB1\*02:01*   5     1.01   2.02
  8    *A\*02:01*, *B\*44:02*, *C\*05:01*, *DRB1\*01:01*, *DQB1\*05:01*   5     1.01   2.02
  9    *A\*02:01*, *B\*07:02*, *C\*07:02*, *DRB1\*15:01*, *DQB1\*06:02*   4     0.81   1.62
  10   *A\*24:02*, *B\*45:01*, *C\*16:01*, *DRB1\*10:01*, *DQB1\*05:01*   4     0.81   1.62
  11   *A\*02:01*, *B\*44:02*, *C\*05:01*, *DRB1\*11:01*, *DQB1\*03:01*   4     0.81   1.62
                                                                                       31.17

HF, haplotype frequency; ID, identification; *N*, number of observed haplotypes; PHF, population haplotype frequency.

![The 11 most frequent haplotypes are present in the 31.17% of the patients of our cohort. Each column represents the accumulated percentage of individuals that have each haplotype (referenced in *Table* [4](#ehf212406-tbl-0004){ref-type="table"} as ID) and its previous ones.](EHF2-6-388-g001){#ehf212406-fig-0001}

Lastly, we focused on the two main etiological causes (DCM and IHF) ([*Tables S2--S7*](#ehf212406-supitem-0001){ref-type="supplementary-material"}). In this context, we found that the frequent haplotype A\*29:02‐B\*44:03‐C\*16:01‐DRB1\*07:01‐DQB1\*02:02 was not present in any of the DCM patients. Moreover, the haplotype A\*01:01‐B\*08:01‐C\*07:01‐DQB1\*02:01‐DRB1\*03:01 (1.19%) was found only once.

Discussion {#ehf212406-sec-0013}
==========

The increased incidence and prevalence of congestive HF have led to the need for novel treatment strategies, including cell‐based therapies. Translating cell administration into the clinic requires the ability to deliver a safe and efficacious product that is ready‐to‐use at the optimal dosage. Allogeneic cell therapy is immediately available and provides a high number of cells[20](#ehf212406-bib-0020){ref-type="ref"}; however, it is clearly a disruptive concept in biology. The standard immunologic dogma holds that any foreign tissue will elicit an immune reaction.[20](#ehf212406-bib-0020){ref-type="ref"} This is clearly apparent in whole organ, tissue, or cell transplants in which aggressive immunosuppression is necessary to protect allografts from rejection.[21](#ehf212406-bib-0021){ref-type="ref"} Thus, the analysis of histocompatibility is most relevant in this field, where differences between the donor\'s HLA alleles and the recipient\'s trigger the immune system to reject the transplant. The World Marrow Donor Association guidelines for establishing the extent and quality of histocompatibility testing for unrelated donor registries, umbilical cord blood banks, and transplant centres involved an international exchange of cells for allogeneic therapy.[22](#ehf212406-bib-0022){ref-type="ref"}

As the field of cell‐based therapy evolves, it has become evident that various cell types -- mesenchymal stem cells (MSCs) being the prototype -- have sufficient ability to evade and/or suppress the immune system to the extent that they may be used as allografts without requiring concomitant immunosuppression.[23](#ehf212406-bib-0023){ref-type="ref"}, [24](#ehf212406-bib-0024){ref-type="ref"} Moreover, increasing evidence has suggested that the effect of infused MSCs is not direct, but rather due to paracrine signalling. Paracrine signalling is consistent with findings in which a low number of retained or seeded cells could promote restorative effects, such as forming vessels to protect resident cardiomyocytes from apoptosis, and mobilize host stem or progenitor cells to potentiate both vascularization and cardiomyogenesis.[25](#ehf212406-bib-0025){ref-type="ref"}, [26](#ehf212406-bib-0026){ref-type="ref"} Thus, alternative cell sources are being examined, including pluripotent stem cells (iPS). The iPS cells are in the preclinical stage, can be generated after inducing the expression of transcription factors associated with pluripotency, and exhibit unlimited self‐renewal and differentiation to many cell lineage types.[27](#ehf212406-bib-0027){ref-type="ref"}, [28](#ehf212406-bib-0028){ref-type="ref"} Clinically, the pluripotency state of iPS allows for a wide range of disease treatments, and their pre‐differentiation *ex vivo* may guarantee their safeness.[29](#ehf212406-bib-0029){ref-type="ref"}, [30](#ehf212406-bib-0030){ref-type="ref"}, [31](#ehf212406-bib-0031){ref-type="ref"} Nevertheless, their high proliferation rate increases the risks associated with products containing iPS (e.g. risk of tumour formation).[32](#ehf212406-bib-0032){ref-type="ref"} Indeed, in contrast to MSCs, derivatives from iPS can currently only be used for autologous cell administration. Thus, it is necessary to generate iPS banks for HLA‐matched allogeneic cell therapy based on known donor and recipient HLA types. Moreover, the major purposes of developing these iPS banks are to ensure cost‐effectiveness, solve the issue of high time consumption in processing autologous iPS or derivatives, and guarantee their utility for acute patients.[33](#ehf212406-bib-0033){ref-type="ref"}

The presented results showed that the most common five‐loci haplotype detected was A\*01:01‐B\*08:01‐C\*07:01‐DRB1\*03:01‐DQB1\*02:01 (3.04%), which had a haplotype frequency of 6.07% per patient in our cohort. This HLA‐estimated haplotype within our cohort of patients is common and conserved in North European Caucasians.[34](#ehf212406-bib-0034){ref-type="ref"}, [35](#ehf212406-bib-0035){ref-type="ref"}, [36](#ehf212406-bib-0036){ref-type="ref"} In particular, when we consider the Allele Frequency Net Database, the haplotype frequency of A\*01:01‐B\*08:01‐C\*07:01‐DQB1\*02:01‐DRB1\*03:01 in North European Caucasians is over 3%. Remarkably, 31.17% of patients in our cohort would be covered by the 11 most frequent haplotypes. This finding from a real setting is in agreement with that previously reported by Gourraud *et al*.[37](#ehf212406-bib-0037){ref-type="ref"} These authors developed a mathematical model and calculated that, in order to obtain iPS for the 20 most frequent HLA haplotypes, 26 000 European‐American donors would need to be analysed and 50% would be compatible. This confirms that relatively few, but very well selected, donors would give rise to iPS lines with a very important clinical utility. To carry out the screening and identify the largest number of possible donors, it would be necessary to collaborate with multiple centres worldwide.[38](#ehf212406-bib-0038){ref-type="ref"} This study searched among potential bone marrow donors and samples preserved in umbilical cord banks, because both are already HLA typed. The findings from this study will be part of a subsequent study of samples stored in the Catalan Blood and Tissue Bank (BST). The search and selection of HLA homozygous cord units for the 11 most frequent haplotypes could extend future administrations of therapeutic cells.

Remarkably, despite further studies using a large cohort of HF patients are warranted to potentially assess statistical significances, our findings suggest a protective role for some haplotypes such as HLA‐B\*08:01 and HLA‐DQB1\*03:01, which are underrepresented in DCM and IHF patients, respectively. In contrast, the haplotypes HLA‐DRB1\*04:03, HLA‐DRB1\*04:04, and HLA‐DRB1\*04:05 could be associated with DCM because their frequencies are higher compared with IHF patients and control subjects (reference database).

In sum, the present study revealed, for the first time, the most frequent HLA allele combinations within a cohort of ambulatory HF patients. Autologous administration of MSC and iPS is still preferred for regenerative purposes because the rejection risks are avoided. However, our findings suggest that safe iPS‐based products, e.g. predifferentiated cardiomyocytes or endothelial cells, can be useful for treating these patients in future clinical trials if the recipient and donor are HLA matched. Indeed, an iPS bank of 11 cell lines will cover almost one‐third of this patient population.
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